참고문헌 (22)

1. 10.1016/j.jacc.2016.03.513 1. Levine GN, Bates ER, Bittl JA, Brindis RG, Fihn SD, Fleisher LA, et al. 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol 2016; 68: 1082-1115. 

   상세보기

2. 10.1056/NEJMoa0706482 2. Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007; 357: 2001-2015. 

   상세보기

3. 10.1056/NEJMoa0904327 3. Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009; 361: 1045-1057. 

   상세보기

4. 10.1016/j.ijcard.2017.07.103 4. Watti H, Dahal K, Zabner HG, Katikaneni P, Modi K, Abdulbaki A. Comparison of prasugrel and ticagrelor in patients with acute coronary syndrome undergoing percutaneous coronary intervention: A meta-analysis of randomized and non-randomized studies. Int J Cardiol 2017; 249: 66-72. 

   상세보기

5. 10.1161/CIRCULATIONAHA.116.024823 5. Motovska Z, Hlinomaz O, Miklik R, Hromadka M, Varbarovsky I, Dusek J, et al. Prasugrel versus ticagrelor in patients with acute myocardial infarction treated with primary percutaneous coronary intervention: Multicenter randomized PRAGUE-18 Study. Circulation 2016; 134: 1603-1612. 

   상세보기

6. 10.1016/j.jjcc.2017.05.003 6. Park KH, Jeong MH, Kim HK, Ahn TH, Seung KB, Oh DJ, et al. Comparison of prasugrel versus clopidogrel in Korean patients with acute myocardial infarction undergoing successful revascularization. J Cardiol 2018; 71: 36-43. 

   상세보기

7. 10.1016/j.ijcard.2016.04.044 7. Park KH, Jeong MH, Ahn Y, Ahn TH, Seung KB, Oh DJ, et al. Comparison of short-term clinical outcomes between ticagrelor versus clopidogrel in patients with acute myocardial infarction undergoing successful revascularization: From Korea Acute Myocardial Infarction Registry-National Institutes of Health. Int J Cardiol 2016; 215: 193-200. 

   상세보기

8. 10.1253/circj.CJ-16-0061 8. Kim JH, Chae SC, Oh DJ, Kim HS, Ahn Y, Cho MC, et al. Multicenter cohort study of acute myocardial infarction in Korea: Interim analysis of the Korea Acute Myocardial Infarction Registry-National Institutes of Health Registry. Circ J 2016; 80: 1427-1436. 

   

9. 10.1093/eurheartj/ehs184 9. Thysessen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR, White HD, et al. Third universal definition of myocardial infarction. Eur Heart J 2012; 33: 2551-2567. 

   상세보기

10. 10.1161/CIRCULATIONAHA.110.009449 10. Mehran R, Rao SV, Bhatt DL, Gibson CM, Caixeta A, Eikelboom J, et al. Standardized bleeding definitions for cardiovascular clinical trials: A consensus report from the Bleeding Academy in Research Consortium. Circulation 2011; 123: 2736-2747. 

    상세보기

11. 10.1161/CIRCULATIONAHA.106.685313 11. Cutlip DE, Windecker S, Mehran R, Boam A, Cohen DJ, van Es GA, et al. Clinical end points in coronary stent trials: A case for standardized definitions. Circulation 2007; 115: 2344-2351. 

    상세보기

12. 10.1093/aje/kwj047 12. Kurth T, Walker AM, Glynn RJ, Chan KA, Gaziano JM, Berger K, et al. Results of multivariable logistic regression, propensity matching, propensity adjustment, and propensity-based weighting under conditions of nonuniform effect. Am J Epidemiol 2006; 163: 262-270. 

    상세보기

13. 10.1016/j.ijcard.2017.07.103 13. Watti H, Dahal K, Zabher HG, Katikaneni P, Modi K, Abdulbaki A. Comparison of prasugrel and ticagrelor in patients with acute coronary syndrome undergoing percutaneous coronary intervention: A meta-analysis of randomized and non-randomized studies. Int J Cardiol 2017; 249: 66-72. 

    상세보기

14. 10.1093/ehjcvp/pvw003 14. Danchin N, Lettino M, Zeymer U, Widimsky P, Bardaji A, Barrabes JA, et al. Use, patient selection and outcomes of P2Y12 receptor inhibitor treatment in patients with STEMI based on contemporary European registries. Eur Heart J Cardiovasc Pharmacother 2016; 2: 152-167. 

    상세보기

15. 10.1016/j.jcin.2016.02.013 15. Rafique AM, Nayyar P, Wang TY, Mehran R, Baber U, Berger PB, et al. Optimal P2Y12 inhibitor in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: A network meta-analysis. JACC Cardiovasc Interv 2016; 9: 1036-1046. 

    상세보기

16. 10.1056/NEJMoa1205512 16. Roe MT, Armstrong PW, Fox KA, White HD, Prabhakaran D, Goodman SG, et al. Prasugrel versus clopidogrel for acute coronary syndromes without revascularization. N Engl J Med 2012; 367: 1297-1309. 

    상세보기

17. 10.1056/NEJMoa1308075 17. Montalescot G, Bolognese L, Dudek D, Goldstein P, Hamm C, Tanguay JF, et al. Pretreatment with prasugrel in non-ST-segment elevation acute coronary syndromes. N Engl J Med 2013; 369: 999-1010. 

    상세보기

18. 10.1161/CIRCINTERVENTIONS.112.972323 18. Alexopoulos D, Xanthopoulou I, Gkizas V, Kassimis G, Theodoropoulos KC, Markis G, et al. Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with ST-segment elevation myocardial infarction. Circ Cardiovasc Interv 2012; 5: 797-804. 

    상세보기

19. 10.1253/circj.CJ-15-0270 19. Lee YS, Jin CD, Kim MH, Guo LZ, Cho YR, Park K, et al. Comparison of prasugrel and ticagrelor antiplatelet effects in Korean patients presenting with ST-segment elevation myocardial infarction. Circ J 2015; 79: 1248-1254. 

    상세보기

20. 10.1007/s11886-014-0485-4 20. Jeong YH. “East Asian paradox”: Challenge for the current antiplatelet strategy of “one-guideline-fits-all races” in acute coronary syndrome. Curr Cardiol Rep 2014; 16: 485. 

    상세보기

21. 10.1253/circj.CJ-13-1482 21. Saito S, Isshiki T, Kimura T, Ogawa H, Yokoi H, Nanto S, et al. Efficacy and safety of adjusted-dose prasugrel compared with clopidogrel in Japanese patients with acute coronary syndrome: The PRAFIT-ACS study. Circ J 2014; 78: 1684-1692. 

    상세보기

22. 10.1016/j.jacc.2017.11.008 22. Motovska Z, Hlinomaz O, Kala P, Hromadka M, Knot J, Varvarovsky I, et al. 1-Year outcomes of patients undergoing primary angioplasty for myocardial infarction treated with prasugrel versus ticagrelor. J Am Coll Cardiol 2018; 71: 371-381. 

    상세보기